Lotta J Seppala1, Esther M M van de Glind1, Joost G Daams2, Kimberley J Ploegmakers1, Max de Vries1, Anne M A T Wermelink1, Nathalie van der Velde3. 1. Department of Internal Medicine, Section of Geriatric Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands; Amsterdam Public Health Research Institute, Amsterdam, the Netherlands. 2. Medical library, Academic Medical Center, Amsterdam, the Netherlands. 3. Department of Internal Medicine, Section of Geriatric Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands; Amsterdam Public Health Research Institute, Amsterdam, the Netherlands. Electronic address: n.vandervelde@amc.uva.nl.
Abstract
BACKGROUND AND OBJECTIVE: The use of psychotropic medication and cardiovascular medication has been associated with an increased risk of falling. However, other frequently prescribed medication classes are still under debate as potential risk factors for falls in the older population. The aim of this systematic review and meta-analysis is to evaluate the associations between fall risk and nonpsychotropic and noncardiovascular medications. METHODS AND DESIGN: A systematic review and meta-analysis. A search was conducted in Medline, PsycINFO, and Embase. Key search concepts were "falls," "aged," "medication," and "causality." Studies were included that investigated nonpsychotropic and noncardiovascular medications as risk factors for falls in participants ≥60 years or participants with a mean age ≥70 years. A meta-analysis was performed using the generic inverse variance method, pooling unadjusted and adjusted odds ratio (OR) estimates separately. RESULTS: In a qualitative synthesis, 281 studies were included. The results of meta-analysis using adjusted data were as follows (a pooled OR [95% confidence interval]): analgesics, 1.42 (0.91-2.23); nonsteroidal anti-inflammatory drugs (NSAIDs), 1.09 (0.96-1.23); opioids, 1.60 (1.35-1.91); anti-Parkinson drugs, 1.54 (0.99-2.39); antiepileptics, 1.55 (1.25-1.92); and polypharmacy, 1.75 (1.27-2.41). Most of the meta-analyses resulted in substantial heterogeneity that did not disappear after stratification for population and setting in most cases. In a descriptive synthesis, consistent associations with falls were observed for long-term proton pump inhibitor use and opioid initiation. Laxatives showed inconsistent associations with falls (7/20 studies showing a positive association). CONCLUSION: Opioid and antiepileptic use and polypharmacy were significantly associated with increased risk of falling in the meta-analyses. Long-term use of proton pump inhibitors and opioid initiation might increase the fall risk. Future research is necessary because the causal role of some medication classes as fall-risk-increasing drugs remains unclear, and the existing literature contains significant limitations.
BACKGROUND AND OBJECTIVE: The use of psychotropic medication and cardiovascular medication has been associated with an increased risk of falling. However, other frequently prescribed medication classes are still under debate as potential risk factors for falls in the older population. The aim of this systematic review and meta-analysis is to evaluate the associations between fall risk and nonpsychotropic and noncardiovascular medications. METHODS AND DESIGN: A systematic review and meta-analysis. A search was conducted in Medline, PsycINFO, and Embase. Key search concepts were "falls," "aged," "medication," and "causality." Studies were included that investigated nonpsychotropic and noncardiovascular medications as risk factors for falls in participants ≥60 years or participants with a mean age ≥70 years. A meta-analysis was performed using the generic inverse variance method, pooling unadjusted and adjusted odds ratio (OR) estimates separately. RESULTS: In a qualitative synthesis, 281 studies were included. The results of meta-analysis using adjusted data were as follows (a pooled OR [95% confidence interval]): analgesics, 1.42 (0.91-2.23); nonsteroidal anti-inflammatory drugs (NSAIDs), 1.09 (0.96-1.23); opioids, 1.60 (1.35-1.91); anti-Parkinson drugs, 1.54 (0.99-2.39); antiepileptics, 1.55 (1.25-1.92); and polypharmacy, 1.75 (1.27-2.41). Most of the meta-analyses resulted in substantial heterogeneity that did not disappear after stratification for population and setting in most cases. In a descriptive synthesis, consistent associations with falls were observed for long-term proton pump inhibitor use and opioid initiation. Laxatives showed inconsistent associations with falls (7/20 studies showing a positive association). CONCLUSION: Opioid and antiepileptic use and polypharmacy were significantly associated with increased risk of falling in the meta-analyses. Long-term use of proton pump inhibitors and opioid initiation might increase the fall risk. Future research is necessary because the causal role of some medication classes as fall-risk-increasing drugs remains unclear, and the existing literature contains significant limitations.
Authors: Julie A Womack; Terrence E Murphy; Christopher T Rentsch; Janet P Tate; Harini Bathulapalli; Alexandria C Smith; Jonathan Bates; Samah Jarad; Cynthia L Gibert; Maria C Rodriguez-Barradas; Phyllis C Tien; Michael T Yin; Thomas M Gill; Gary Friedlaender; Cynthia A Brandt; Amy C Justice Journal: J Acquir Immune Defic Syndr Date: 2019-11-01 Impact factor: 3.731
Authors: Anthony V Herrera; Linda Wastila; Jessica P Brown; Hegang Chen; Steven R Gambert; Jennifer S Albrecht Journal: J Head Trauma Rehabil Date: 2021 Sep-Oct 01 Impact factor: 2.710
Authors: Manuel Montero-Odasso; Nathalie van der Velde; Finbarr C Martin; Mirko Petrovic; Maw Pin Tan; Jesper Ryg; Sara Aguilar-Navarro; Neil B Alexander; Clemens Becker; Hubert Blain; Robbie Bourke; Ian D Cameron; Richard Camicioli; Lindy Clemson; Jacqueline Close; Kim Delbaere; Leilei Duan; Gustavo Duque; Suzanne M Dyer; Ellen Freiberger; David A Ganz; Fernando Gómez; Jeffrey M Hausdorff; David B Hogan; Susan M W Hunter; Jose R Jauregui; Nellie Kamkar; Rose-Anne Kenny; Sarah E Lamb; Nancy K Latham; Lewis A Lipsitz; Teresa Liu-Ambrose; Pip Logan; Stephen R Lord; Louise Mallet; David Marsh; Koen Milisen; Rogelio Moctezuma-Gallegos; Meg E Morris; Alice Nieuwboer; Monica R Perracini; Frederico Pieruccini-Faria; Alison Pighills; Catherine Said; Ervin Sejdic; Catherine Sherrington; Dawn A Skelton; Sabestina Dsouza; Mark Speechley; Susan Stark; Chris Todd; Bruce R Troen; Tischa van der Cammen; Joe Verghese; Ellen Vlaeyen; Jennifer A Watt; Tahir Masud Journal: Age Ageing Date: 2022-09-02 Impact factor: 12.782
Authors: N M van Schoor; E Dennison; M V Castell; C Cooper; M H Edwards; S Maggi; N L Pedersen; S van der Pas; J J M Rijnhart; P Lips; D J H Deeg Journal: Semin Arthritis Rheum Date: 2020-02-19 Impact factor: 5.532
Authors: Jannis Bodden; Gabby B Joseph; Silvia Schirò; John A Lynch; Nancy E Lane; Charles E McCulloch; Michael C Nevitt; Thomas M Link Journal: Arthritis Res Ther Date: 2021-05-22 Impact factor: 5.156
Authors: Lotta J Seppala; Mirko Petrovic; Jesper Ryg; Gulistan Bahat; Eva Topinkova; Katarzyna Szczerbińska; Tischa J M van der Cammen; Sirpa Hartikainen; Birkan Ilhan; Francesco Landi; Yvonne Morrissey; Alpana Mair; Marta Gutiérrez-Valencia; Marielle H Emmelot-Vonk; María Ángeles Caballero Mora; Michael Denkinger; Peter Crome; Stephen H D Jackson; Andrea Correa-Pérez; Wilma Knol; George Soulis; Adalsteinn Gudmundsson; Gijsbertus Ziere; Martin Wehling; Denis O'Mahony; Antonio Cherubini; Nathalie van der Velde Journal: Age Ageing Date: 2021-06-28 Impact factor: 10.668
Authors: Amy L Shaver; Collin M Clark; Mary Hejna; Steven Feuerstein; Robert G Wahler; David M Jacobs Journal: Pharmacoepidemiol Drug Saf Date: 2021-02-16 Impact factor: 2.732
Authors: Shahar Shmuel; Virginia Pate; Marc J Pepin; Janine C Bailey; Yvonne M Golightly; Laura C Hanson; Til Stürmer; Rebecca B Naumann; Danijela Gnjidic; Jennifer L Lund Journal: J Am Geriatr Soc Date: 2021-07-22 Impact factor: 5.562